Biotech is going to be eaten by software, that's not in question. It's clear that Kleiner lost their first bet on health startups, which means that I'm looking forward to seeing the next batch of startups give it a go.
No doubt, biotech will be "eaten" by software. But the crowded market of biotech software has many viable open source alternatives. Besides, many tools have been developed or are being developed by established companies.<p>Yet, I don't see much evidence of growth. Looks like 'play money' for investors.